Bibliography
- Srinivasan BT, Jarvis J, Khunti K, Davies MJ. Recent advances in the management of type 2 diabetes mellitus: a review. Postgrad Med J. 2008;84:524-31
- Murphy KG, Dhillo WS, Bloom SR. Gut peptides in the regulation of food intake and energy homeostasis. Endoc Rev 2006;27:719-27
- Jones RM, Leonard JN, Buzard DJ, Lehmann J. GPR119 agonists for the treatment of type 2 diabetes. Expert Opin Ther 2009;19(10):1339-59
- Wook K, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 2008;60:470-512
- Bebernitz GR, Beaulieu V, Dale BA, et al. Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes. J Med Chem 2009;52:6142-52
- Tonlinson JW, Walker EA, Bujalska IJ, et al. 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 2004;25:831-66
- Espinosa I, Fogelfeld L. Tagatose: from a sweetener to a new diabetic medication? Expert Opin Investig Drugs 2010;19(2):285-94
- Totsune K, Takahashi K, Arihara Z, et al. Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with Type 2 diabetes mellitus: association with progress of diabetic nephropathy. Peptides 2004;25:1809-14
- Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res 2010;106:1319-31
- Sheetz MJ, Aiello LP, Davis MD, et al. The effect of the oral PKC β inhibitor ruboxistaurin on vision loss in two Phase 3 studies. Invest Ophthalmol Vis Sci 2013;54(3):1750-7
- White GE, Iqbal AJ, Greaves DR. CC chemokine receptors and chronic inflammation-therapeutic opportunities and pharmacological challenges. Pharmacol Rev 2013;65:47-89
- Xue CB, Wang A, Han Q, et al. Discovery of INCB8761/PF-4136309, a potent, selective, and orally bioavailable CCR2 antagonist. ACS Med Chem Lett 2011;2:913-18
- Meyers MJ, Arhancet GB, Hockerman SL, et al. Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy. J Med Chem 2010;53(16):5979-6002
- Rohof WO, Lei A, Hirsch DP, et al. The effects of a novel metabotropic glutamate receptor 5 antagonist (AZD2066) on transient lower oesophageal sphincter relaxations and reflux episodes in healthy volunteers. Aliment Pharmacol Ther 2012;35:1231-42
- Dunlop J, Watts SW, Barrett JE, et al. Characterization of vabicaserin (SCA-136), a selective 5-hydroxytryptamine 2C receptor agonist. J Pharmacol Exp Ther 2011;337:673-80
- Arsenault BJ, Boekholdt SM, Kastelein JJP. Varespladib: targeting the inflammatory face of atherosclerosis. Eur Heart J 2011;32:923-6
- Ladenson PW, Kristensen JD, Ridgway EC, et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med 2010;362:906-16
- Aspinall RJ, Pockros PJ. SCV PJ-07 (SciClone Pharmaceuticals/Verta). Curr Opin Investig Drugs 2006;7:180-5
- Gao W, Reiser PJ, Coss CC, et al. Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. Endocrinology 2005;146:4887-97